SEARCH

SEARCH BY CITATION

References

  • 1
    De La Peyronie F. Sur quelques obstaclesqui sópposent à l'éjaculation nautrelle de la semence. Mem Acad Royale Chir 1743; 1: 33742.
  • 2
    El-Sakka AI, Hassoba HM, Chui RM, Bhatnagar RS, Dahiya R, Lue TF. An animal model of Peyronie's like condition associated with an increase of transforming growth factor β mRNA and protein expression. J Urol 1997; 158: 228490.
  • 3
    El-Sakka AI, Hassoba HM, Pillarisetty RJ, Dahiya R, Lue TF. Peyronie's disease is associated with an increase in transforming growth factor-beta protein expression. J Urol 1997; 158: 13914.
  • 4
    Bivalacqua TJ, Champion HC, Leungwattanakij S, Yang DY, Hyun JS, Abdel-Mageed AB, et al. Evaluation of nitric oxide synthase and arginase in the induction of a Peyronie's like condition in the rat. J Androl 2001; 22: 497506.
  • 5
    Kucharewicz I, Kowal K, Buczko W, Bodzenta-Lukaszyk A. The plasmin system in airway remodeling. Thromb Res 2003; 112: 17.
  • 6
    Van de Water L. Mechanisms by which fibrin and fibronectin appear in healing wounds: implications for Peyronie's disease. J Urol 1997; 157: 30610.
  • 7
    Davila HH, Magee TR, Zuniga FI, Rajfer J, Gonzalez-Cadavid NF. Peyronie's disease is associated with an increase of plasminogen activator inhibitor-1 in fibrotic plaque. Urology 2005; 65: 6458.
  • 8
    Davila HH, Ferrini MG, Rajfer J, Gonzalez-Cadavid NF. Fibrin as an inducer of fibrosis in the tunica albuginea of the rat: a new animal model of Peyronie's disease. BJU Int 2003; 91: 8308.
  • 9
    Nagase H, Woessner JF. Matrix metalloproteinases. J Biol Chem 1999; 274: 214914.
  • 10
    Ryu JK, Piao S, Shin HY, Zhang L, Jin H, Han JY, et al. IN-1130, A novel transforming growth factory type 1 receptor kinase (ALK 5) inhibitor regresses fibrotic plaque and corrects penile curvature in a rat model of Peyronie's Disease. Annual Meeting of the American Urological Association, 2007, May 1924, 2007, Anaheim, California, USA. Abstract 749.
  • 11
    Del Carlo M, Levine LA, Cole AA. Differential regulation of matrix metalloproteinases (MMP) and tissue inhibitors of matrix metalloproteinases (TIMPs) by interleukin-1 β (IL-1 β) and transforming growth factor β (TGF-β in Peyronie's fibroblasts. Annual Meeting of the American Urological Association, 2007, May 19–24, 2007, Anaheim, California, USA. J Urol 2007; 177 (4 Suppl): Abstract 755.
  • 12
    Qian A, Meals RA, Rajfer J, Gonzalez-Cadavid NF. Comparison of gene expression profiles between Peyronie's disease and Dupuytren's contracture. Urology 2004; 64: 399404.
  • 13
    Deveci S, Hopps CV, O'Brien K, Parker M, Guhring P, Mulhall JP. Defining the clinical characteristics of Peyronie's disease in young men. J Sex Med 2007; 4: 48590.
  • 14
    Williams JL, Thomas GG. The natural history of Peyronie's disease. J Urol 1970; 103: 756.
  • 15
    Gelbard MK, Dorey F, James K. The natural history of Peyronie's disease. J Urol 1990; 144: 13769.
  • 16
    Deveci S, Hopps CV, O'Brien K, Parker M, Guhring P, Mulhall JP. A retrospective review of 307 men with Peyronie's disease. J Urol 2002; 168: 10759.
  • 17
    Scott WW, Scardino PL. A new concept in the treatment of Peyronie's disease. South Med J 1948; 41: 1737.
  • 18
    Sikka SC, Hellstrom WJ. Role of oxidative stress and antioxidants in Peyronie's disease. Int J Impot Res 2002; 14: 35360.
  • 19
    Gholami SS, Gonzalez-Cadavid NF, Lin CS, Rajfer J, Lue TF. Peyronie's disease: a review. J Urol 2002; 169: 123441.
  • 20
    Pryor JP, Farell CF. Controlled clinical trial of vitamin E in Peyronie's Disease. Prog Reprod Biol 1983; 9: 415.
  • 21
    Furst DE, Munster T. Nonsteroidal anti-inflammatory drugs, disease-modifying antirheumatic drugs, nonopioid analgesics & drugs used in gout. In: Basic and Clinical Pharmacology. BertramG, editor. Katzung Lange: New York ; 2001.
  • 22
    Akkus E, Carrier S, Rehman J, Breza J, Kadioglu A, Lue TF. Is colchicine effective in Peyronie's disease? A pilot study. Urology 1994; 44: 2915.
  • 23
    Kadioglu A, Tefekli A, Koksal T, Usta M, Erol H. Treatment of Peyronie's disease with oral colchicine: long term results and predictive parameters of successful outcome. Int J Impot Res 2000; 12: 16975.
  • 24
    Safarinejad MR. Therapeutic effects of colchicine in the management of Peyronie's disease: a randomized double-blind, placebo-controlled study. Int J Impot Res 2004; 16: 23843.
  • 25
    Zarafonetis CJ, Horrax TM. Treatment of Peyronie's disease with potassium para-aminobenzoate (potaba). J Urol 1959; 81: 7702.
  • 26
    Hasche-Klunder R. Treatment of Peyronie's disease with para-aminobenzoacidic potassium (Potoba) (author's translation). Urologe A 1978; 17: 2247.
  • 27
    Weidner W, Schroeder-Printzen I, Rudnick J. Randomized prospective placebo-controlled therapy of Peyronie's disease (IPP) with Potaba (aminobenzoate potassium). J Urol 1999; 6: 205.
  • 28
    Weidner W, Hauck EW, Schnitker J. Peyronie's Disease Study Group of Andrological Group of German Urologists. Potassium paraaminobenzoate (Potaba) in the treatment of Peyronie's disease: a prospective, placebo-controlled, randomized study. Eur Urol 2005; 47: 5306.
  • 29
    Ralph DJ, Brooks MD, Bottazzo GF, Pryor JP. The treatment of Peyronie's disease with tamoxifen. Br J Urol 1992; 70: 64851.
  • 30
    Colletta AA, Wakefield LM, Howell FV, Van Roozendaal KE, Danielpour D, Ebbs SR, et al. Anti-oestrogens induce the secretion of active transforming growth factor beta from human fetal fibroblasts. Br J Cancer 1990; 62: 4059.
  • 31
    Teloken C, Rhoden EL, Grazziotin TM, Ros CT, Sogari PR, Souto CA. Tamoxifen versus placebo in the treatment of Peyronie's disease. J Urol 1999; 162: 20035.
  • 32
    Biagiotti G, Cavallini G. Acetyl-L-carnitine vs tamoxifen in the oral therapy of Peyronie's disease: a preliminary report. BJU Int 2001; 88: 637.
  • 33
    Valente EG, Vernet D, Ferrini MG, Qian A, Rajfer J, Gonzalez-Cadavid NF. L-Arginine and phosphodiesterase (PDE) inhibitors counteract fibrosis in the Peyronie's fibrotic plaque and related fibroblast cultures. Nitric Oxide 2003; 9: 22944.
  • 34
    Brant WO, Dean RC, Lue TF. Treatment of Peyronie's disease with oral pentoxifylline. Nat Clin Pract Urol 2006; 3: 1115.
  • 35
    Martin DJ, Badwan K, Parker M, Mulhall JP. Transdermal application of verapamil gel to the penile shaft fails to infiltrate the tunica albuginea. J Urol 2002; 168: 24835.
  • 36
    Fitch WP 3rd, Easterling WJ, Talbert RL, Bordovsky MJ, Mosier M. Topical verapamil HC1, topical trifluoperazine, and topical magnesium sulfate for the treatment of Peyronie's disease — a placebo-controlled pilot study. J Sex Med 2007; 4: 47784.
  • 37
    Levine LA. Comment on: Topical verpamil HC1, topical trfluoperazine, and topical magnesium sulfate for the treatment of Peyronie's disease — a placebo-controlled pilot study. J Sex Med 2007; 4: 10812.
  • 38
    Bodner H, Howard AH, Kaplan JH. Peyronie's disease: cortisone-hyaluronidase-hydrocortisone therapy. J Urol 1954; 4003.
  • 39
    Winter CC, Khanna R. Peyronie's disease: results with dermojet injection of dexamethasone. J Urol 1975; 114: 898900.
  • 40
    Williams G, Green NA. The non-surgical treatment of Peyronie's disease. Br J Urol 1980; 52: 3925.
  • 41
    Gelbard MK, Walsh R, Kaufman JJ. Collagenase for Peyronie's disease experimental studies. Urol Res 1982; 10: 13540.
  • 42
    Gelbard MK, Linkner A, Kaufman JJ. The use of collagenase in the treatment of Peyronie's disease. J Urol 1985; 134: 2803.
  • 43
    Gelbard MK, James K, Riach P, Dorey F. Collagenase vs. placebo in the treatment of Peyronie's disease: a double blind study. J Urol 1993; 149: 568.
  • 44
    Roth M, Eickelberg O, Kohler E, Erne P, Block LH. Ca2+ channel blockers modulate metabolism of collagens within the extracellular matrix. Proc Natl Acad Sci USA 1996; 93: 547882.
  • 45
    Mulhall J P, Anderson MS, Lubrano T, Shankey TV. Peyronie's disease cell culture models: phenotypic, genotypic and functional analyses. Int J Impot Res 2002; 14: 397405.
  • 46
    Levine LA, Merrick PF, Lee RC. Intralesional verapamil injection for the treatment of Peyronie's disease. J Urol 1994; 151: 15224.
  • 47
    Rehman J, Benet A, Melman A. Use of intralesional verapamil to dissolve Peyronie's disease plaque: a long term single-blind study. Urology 1998; 51: 6206.
  • 48
    Levine LA, Estrada CR. Intralesional verapamil for the treatment of Peyronie's disease: a review. Int J Impot Res 2002; 14: 3248.
  • 49
    Bennett NE, Guhring, P, Mulhall JP. Intralesional verapamil prevents the progression of Peyronie's Disease. Urology 2007; 69: 11814.
  • 50
    Duncan MR, Berman B, Nseyo UO. Regulation of the proliferation and biosynthetic activities of cultured human Peyronie's disease fibroblasts by interferons-alpha, -beta and -gamma. Scand J Urol Nephrol 1991; 25: 8994.
  • 51
    Wegner HE, Andreson R, Knipsel HH, Miller K. Treatment of Peyronie's disease with local interferon-alpha-2b. Eur Urol 1995; 28: 23640.
  • 52
    Wegner HE, Andresen R, Knipsel HH, Miller K. Local interferon-alpha 2b is not an effective treatment in early-stage Peyronie's disease. Eur Urol 1997; 32: 1903.
  • 53
    Ahuja S, Bivalacqua TJ, Case J, Vincent M, Sikka SC, Hellstrom WJ. A pilot study demonstrating clinical benefit from intralesional interferon alpha 2B in the treatment of Peyronie's disease. J Androl 1999; 20: 4448.
  • 54
    Dang G, Matern R, Bivalacqua TJ, Sikka S, Hellstrom WJ. Intralesional interferon-alpha-2B injections for the treatment of Peyronie's disease. South Med J 2004; 97: 426.
  • 55
    Hellstrom WJ, Kendirci M, Matern R, Cockerham Y, Myers L, Sikka SC, et al. Single-blind, multicenter placebo-controlled parallel study to asses the safety and efficacy of intralesional interferon alpha-2B for minimally invasive treatment for Peyronie's disease. J Urol 2006; 176: 3948.
  • 56
    Levine LA. Review of current nonsurgical management of Peyronie's disease. Int J Impot Res 2003; 15: S11320.
  • 57
    Hauck EW, Altinkilic BM, Ludwig M, Ludecke G, Schroeder-Printzen I, Arens C, et al. Extracorporeal shock wave therapy in the treatment of Peyronie's disease. First results of a case-controlled approach. Eur Urol 2000; 38: 66370.
  • 58
    Hatzichristodoulou G, Meisner C, Liske P, Stenzl A, Lahm S. Efficacy of extracorporeal shock wave therapy (ESWT) in patients with Peyronie's disease (PD)-first results of a prospective, randomized, placebo-controlled, single-blind study. American Urological Association 2006 Annual Meeting. May 20–25, 2006, Atlanta, Georgia, USA. J Urol 2006; 175 (4 Suppl): Abstract 993.
  • 59
    Hatzichristodoulou G, Meisner C, Stenzyl A, Lahm S. Efficacy of extracorporeal shock wave therapy on plaque size and sexual function in patients with Peyronie's Disease — results of a prospective, randomized, placebo-controlled study. Annual Meeting of the American Urological Association, 2007, May 19–24, 2007, Anaheim, California, USA. J Urol 2007; 177(4 Suppl): Abstract 747.
  • 60
    Riedl CR, Plas E, Engelhard P, Daha K, Pfluger H. Lontophoresis for treatment of Peyronie's disease. J Urol 2000; 163: 959.
  • 61
    Montorsi F, Salonia A, Guazzoni G, Barbieri L, Colombo R, Brausi M. Transdermal electromotive multi-drug administration for Peyronie's disease: preliminary results. J Androl 2000; 21: 8590.
  • 62
    Di Stasi SM, Giannantoni A, Capelli G, Jannini EA, Virgili G, Storti L, et al. Transdermal electromotive administration of verapamil and dexamethasone for Peyronie's disease. BJU Int 2003; 91: 8259.
  • 63
    Di Stasi SM, Giannantoni A, Stephen RL, Capelli G, Glurioli A, Jannini EA, et al. A prospective, randomized study using transdermal electromotive administration of verapamil and dexamethasone for Peyronie's disease. J Urol 2004; 171: 16058.
  • 64
    Levine LA, Estrada CR, Show W, Cole A. Tunica albuginea tissue analysis after electromotive drug administration. J Urol 2003; 169: 17758.
  • 65
    Greenfield JM, Shah SJ, Levine LA. Verapamil versus saline in electromotive drug administration (EDMA) for Peyronie's disease: a double blind, placebo controlled trial. J Urol 2007; 177: 9725.
  • 66
    Ojingwa JC, Isseroff RR. Electrical stimulation of wound healing. J Invest Dermatol 2003; 121: 112.
  • 67
    Preito Castro RM, Leva Vallejo ME, Regueiro Lopez JC, Anglada Curado FJ, Alvarez Kindelan J, Requena Tapia MJ. Combined treatment with vitamin E and colchicines in the early stages of Peyronie's disease. BJU Int 2003; 91: 5224.
  • 68
    Mirone V, Palmieri A, Granata AM, Piscopo A, Verze P, Ranavolo R. Ultrasound-guided ESWT in Peyronie's disease plaques. Arch Ital Urol Androl 2000; 72: 3847.
  • 69
    Mirone V, Imbimbo C, Palmieri A, Fusco F. Our experience on the association of a new physical and medical therapy in patients suffering from induration penis plastica. Eur Urol 1999; 36: 32730.
  • 70
    Cavallini G, Biagiotti G, Koverech A, Vitali G. Oral propionyl-l-carnitine and intraplaque verapamil in the therapy of advanced and resistant Peyronie's disease. BJU Int 2002; 89: 895900.